Clinical Trial Update: A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AP30663 for cardioversion in atrial fibrillation has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• AP30663

Snippet

Sponsor: Acesion Pharma | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2024-05-06